基因表达检测能够鉴别心脏移植排斥

 
一项最新研究证实，简单的血液检测能够分析患者的基因，能够准确测定心脏移植排斥情况。

AlloMap检测使用实时定量PCR(PCR)和运算法则来分析患者的基因表达。该检测检测出排斥情况，意味着较低的检测成本就能够十分可靠地鉴别出患者是否对心脏移植不会排斥。该检测最主要优点是鉴别出低风险患者，这些患者能够使用非创伤性方法进行监测和处理；以及那些需要积极使用强效免疫药物的患者，这些药物常常有严重的副作用。

Gene Expression Test Rules Out Transplant Rejection
 
A new study confirms that a simple blood test that analyzes a patient's genes can accurately detect the absence of heart transplant rejection.

The AlloMap test uses real-time polymerase chain reaction (PCR) and an algorithm to analyze the patient's gene expression. The test rules out rejection, meaning that a low test score very reliably identifies the transplant patient who is not rejecting the transplanted heart. The primary advantage of the test is to identify low-risk patients who can be monitored and managed using noninvasive methods and who may benefit from being more aggressively weaned off intensive immunosuppressive regimens that are associated with serious side effects.